A pilot study concerning the effectiveness of a combination of therapies combating mesothelioma is being conducted at the Center for Cancer Research (CCR) at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. The study will specifically look into whether treating mesothelioma with a combination of drugs, which causes different effects in the drug, would be better than the separate treatments alone.
Patients involved in the study will participate in cycles of different therapies, with the first lasting 30 days and subsequent cycles of 21 days. Each cycle will contain Pentostatin and SS1P given through a vein, and Cyclophosphamide pills taken by mouth at home. Pentostatin is a drug which inhibits RNA reproduction and may also selectively deplete infected cancer stem cells. Cyclophosphamide inhibits DNA replication and also kills cells. SS1P is an immunotoxin therapy, which is designed to attack cells that have mesothelin while leaving healthy cells alone.
There is no charge for the medical care received at NIH Clinical Center. For a list of eligibility criteria and referral contacts, please visit the study’s website.
If you or someone you love has had exposure to asbestos and diagnosed with mesothelioma cancer, you may be entitled to compensation. Contact 1-888-637-6347 today for a no obligation, free consultation.
Cappolino Dodd Krebs LLP – mesothelioma lawyers
[Did You Know: Most studies at the NIH CCR in Maryland regarding malignant mesothelioma are open to anyone in the country if they meet criteria.]